02/03/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/3/2020. This interim guidance, for U.S.-bound travelers and people located in the United States who may have been exposed to 2019-nCoV, was created to provide U.S. public health authorities and other partners with a framework for assessing and managing risk of potential exposures to 2019-nCoV, and implementing public health actions based on a person’s risk level and clinical presentation. It is effective as of February 3, 2020, and does not apply retrospectively to people who have been in China during the previous 14 days and are already in the United States, or those being managed as part of a contact investigation. (Text)
01/31/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 1/31/2020. The Centers for Disease Control and Prevention is working closely with state and local health departments around the country to support person under investigation (PUI) for novel coronavirus (2019-nCoV) specimen referral. It provides steps for state and local health departments to take, and links to the 2019-nCoV PUI case investigation form. (Text)
01/28/2020 12:00 AM EST
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 1/28/2020. Diagnostic testing for the novel coronavirus (2019-nCoV) is undertaken using two approaches: whole genome sequencing, and real-time reverse transcriptase PCR (rRT-PCR). This two-page fact sheet details how sequencing was used primarily in the early days of the outbreak for initial identification of this novel virus and is largely a tool of viral discovery. Currently, almost all diagnostic testing for nCoV is done using rRT-PCR. (PDF)
.png)
No hay comentarios:
Publicar un comentario